Yo-Ting Tsai

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Marijo Bilušić, Sheri McMahon, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2021 · 59 citations · Full text

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Jason M. Redman, Yo-Ting Tsai, Benjamin A. Weinberg et al. · The Oncologist · 2022 · 48 citations · Full text

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Swagata Goswami, Rajeswaran Mani, Jessica Nunes et al. · Blood · 2021 · 37 citations · Full text

Targetable Driver, Hematological Malignancy, C-myc/p21 Axis +15

Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10

Ming‐Hsun Wu, Yo-Ting Tsai, Kuo‐Tai Hua et al. · The Journal of Nutritional Biochemistry · 2012 · 36 citations

Oncology, Matrix Metalloproteinase 10, Oncogenic Agent +8

Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors

Julie Collins, Renee N. Donahue, Yo-Ting Tsai et al. · The Oncologist · 2019 · 26 citations · Full text